proefschrift-rianne-willemsen_com_kleiner_formaat.pdf
(13.75 MB, PDF)
… showed that cetuximab is inferior to cisplatin in case of a curative chemoradiotherapy regimen for HPV-related tumors. [31] Therefore, in patients with HPV-related tumors and contra-indications for cisplatin, carboplatin is currently considered the best alternative, based on previous studies demonstrating the additional value of concurrent carboplatin with radiotherapy. [29] In the adjuvant setting, there is only evidence for platinum-based chemoradiotherapy in case of extranodal extension or … remains challenging to predict which patients will benefit from ICI treatment. Therefore, additional biomarkers and more in-depth patient and tumor characterization are needed for adequate patient selection and to ultimately improve treatment outcome. When HNSCC’s become resistant to ICI treatment, further treatment options are limited. Clinical trials using novel immune modulators (e.g., monalizumab, NCT04590963) are currently ongoing. Additionally, next generation sequencing (NGS) analysis of … Yen, C.Y. Lin, K.P. Chang, and K.F. Lei, Pretreatment subcutaneous adipose tissue predicts the outcomes of patients with head and neck cancer receiving definitive radiation and chemoradiation in Taiwan. Cancer Med, 2018 DOI: 10.1002/cam4.1365. 11. Bishop, S. and W.M. Reed, The provision of enteral nutritional support during definitive chemoradiotherapy in head and neck cancer patients. J Med Radiat Sci, 2015. 62(4): p. 267-76 DOI: 10.1002/jmrs.132. 12. Wang, C., J.M. Vainshtein, M. Veksler, P.E. …